For heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis…. ANDA 206551, held by Accord Hlthcare. Bivalirudin.
As of Nov 16, 2026, ANDA 206551 (Bivalirudin), held by Accord Hlthcare, was first approved by FDA on Nov 22, 2017, with 3 approved supplements and 0 published complete response letters.
Bivalirudin for injection is indicated for use as an anticoagulant for use in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Bivalirudin for injection is a direct thrombin inhibitor indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 22, 2017 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Bivalirudin250MG/VIAL · injectable;intravenous | Bivalirudin | Rx |
| Feb 18, 2025 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 18, 2025 | Supplement 5Labeling · Standard review | Approved | None posted |
| Feb 18, 2025 | Supplement 7Labeling · Standard review | Approved | None posted |
| Nov 22, 2017 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters